TORONTO, Dec. 12 /PRNewswire-FirstCall/ -- MedCap Corp (Pinksheets: MPCPF) is pleased to announce that its Chinese joint venture will produce a rapid diagnostic test kit for the Avian Flu. Previous attempts to manufacture this test kit have been hampered by the fact that the joint venture was not able to get access to the Avian flu antigens necessary to produce the test strips. MedCap's Chinese partners have now acquired access to the Avian Flu antigens that will allow MedCap to produce the rapid diagnostic test strips for the Avian Flu. MedCap will contribute its technology developed with its AccuScan test kits.
There will be two test kits developed. One will be developed to test birds for the avian flu and one will be developed for use by humans. The initial kit will be to detect the Avian flu in birds. Based on estimates by technical staff this initial test kit will be available for the market within 3 to 4 months. The current testing for Avian Flu takes 3 to 7 days and must be done in a laboratory. During this time the virus spreads rapidly infecting an entire flock. The new test kit will use blood and will give results in less than 20 minutes and will be used in the field. This test kit will be used to isolate the infected animals and will potentially save hundreds of thousands of the flock from being destroyed through early detection. Early detection will be a very important aspect for controlling the Avian Flu.
It is expected that this test kit will be used throughout the industry in southeast Asia and will be instrumental in preventing entire flocks from being destroyed. It will also allow regulatory agencies to know if and when the Avian Flu has become prevalent in their areas.
MedCap Corp trades in the United States on the Pinksheets under the symbol "MPCPF."
For further information, please contact Howell Capital at (416) 828 8737 or go to the website at http://www.medccorp.com.
NOTE: This release may contain forward-looking statements that involve uncertainties and risks. Actual results may differ materially from any results predicted. MedCap undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events of circumstances after the date hereof.
CONTACT: Howell Capital for MedCap Corp, +1-416-828-8737